WallStSmart
DRTS

Alpha Tau Medical Ltd

NASDAQ: DRTS · HEALTHCARE · BIOTECHNOLOGY

$9.88
-9.14% today

Updated 2026-06-05

Market cap
$844.55M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.67
Dividend yield
—
52W range
$3 – $12
Volume
0.8M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Alpha Tau Medical Ltd (DRTS) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

DRTS · Alpha Tau Medical Ltd · Price target summary

Current
$9.88
Consensus
$8.67
-12.25%
2030 Target
$27.23
+175.61%
DCF
—
—
5 analysts:
2 Buy2 Hold1 Sell

Management guidance

Alpha Tau Medical has not provided specific revenue guidance through 2030. The company is pre-commercial, with TTM revenue of $0.00 as of May 2026. Management focus is on regulatory milestones (FDA modular PMA submission for cSCC, multiple clinical trial expansions) and clinical data readouts expected in H2 2026, rather than revenue targets.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

DRTS · Alpha Tau Medical Ltd · Revenue & price projection · 2023–2030E

Actual revenue Projected revenue Base case Bull to bear range
Bear case (2030)
$16.17
$0.4B Rev × 3x P/S
Base case (2030)
$27.23
$0.4B Rev × 5x P/S
Bull case (2030)
$43.40
$0.4B Rev × 8x P/S
WallStSmart.com

Financial forecast — research-backed

Metric20252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$0.0B$0.0B$0.0B$0.1B$0.2B$0.4B
Revenue growth——989.0%244.8%176.9%133.3%
EPS$-0.77$-0.52$-0.43$-0.25$0.05$0.35
P/S ratio—5.0x5.0x5.0x5.0x5.0x
Implied price—$0.00$0.85$4.26$11.91$27.23

DRTS · Alpha Tau Medical Ltd · Catalysts & risks

Growth catalysts
+ FDA modular PMA submission and pivotal trial data for recurrent cutaneous squamous cell carcinoma (cSCC) expected H2 2026
+ Regulatory approvals in Japan (MHLW), Europe, and potential FDA breakthrough device designation expansion across multiple cancer indications
+ Pancreatic cancer IMPACT trial expansion to 40 patients; ASCO 2026 presentation of pooled 58-patient pancreatic data showing 100% local disease control
+ Glioblastoma REGAIN trial interim data readout (first 3 patients); head and neck cancer combination therapy (Alpha DaRT + pembrolizumab) podium presentation at AHNS July 2026
+ Commercial launch of Alpha DaRT post-FDA approval; potential milestone payments from strategic partnerships (Oramed $36.9M investment April 2025)
Key risks
- Company is pre-commercial with zero TTM revenue; all projections dependent on regulatory approval and market adoption of novel alpha-emitter therapy
- Clinical trial risks: cSCC pivotal trial endpoint achievement, pancreatic and glioblastoma trial safety/efficacy validation, potential manufacturing/delivery challenges
- Competitive risks from established radiation/immunotherapy platforms; reimbursement uncertainty for localized alpha-radiation therapy as novel modality
- Dilution risk: $300M shelf registration filed April 2026; $100M ATM agreement with H.C. Wainwright announced, indicating capital needs
- Small market cap ($749M) and high cash burn; limited visibility on commercial ramp trajectory post-approval

Methodology

Alpha Tau Medical Ltd's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 5 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 9, 2026.